Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

for the ketamine Abbreviated New Drug Application, which was assigned a Generic Drug User Fee Amendments of 2022 ("GDUFA”) goal date of October 29, 2024. On November 12, 2024, the FDA granted the ...

The authorised ANDA is a therapeutic equivalent of the reference-listed drug (RLD), Corlanor tablets, in the same 5 mg and ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

By penetrating biological barriers and delivering encapsulated drug directly to disease sites, reduces systemic side effects and toxicity while improving the therapy's effectiveness. An application ..

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

Advertisement He wrote that the law is "facially unconstitutional" and "in all applications" that will "irreparably harm ...